Vontobel Holding’s RAPT Therapeutics RAPT Stock Holding History

Vontobel Holding’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,250	Closed	-$311K	–	1184
2021 Q3	$311K	Buy	+1,250	New	+$330K	﹤0.01%	930

Other funds holding RAPT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

KXA

KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vontobel Holding's RAPT Position: Q4 2021 in Review

Vontobel Holding sold out of RAPT Therapeutics (RAPT) in Q4 2021, closing a stake of 1,250 shares — an estimated $311K sold.

Vontobel Holding first reported a position in RAPT in Q3 2021 and held it in 1 quarter. The position peaked at $311K in Q3 2021. 99 funds tracked by Wall St. Rank hold RAPT as of Q4 2021.

Vontobel Holding reported no remaining RAPT Therapeutics position as of Q4 2021 after selling out during the quarter.
Vontobel Holding sold 1,250 RAPT Therapeutics shares in Q4 2021, an estimated $311K.
Vontobel Holding first reported a position in RAPT Therapeutics in Q3 2021 and held it in 1 quarter.
Vontobel Holding's RAPT Therapeutics position peaked at $311K in Q3 2021.
99 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2021.

Based on Vontobel Holding's 13F filing for Q4 2021, filed 10 Feb 2022.